Placebo for Lenvatinib clinical trials

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

This study is looking at a new combination of medicines (Lenvatinib and Pembrolizumab) plus TACE for people with liver cancer that hasn't spread. We want to see if this combination works better than TACE alone to stop the cancer from growing and help people live longer.